Having trouble accessing articles? Reset your cache.

Jan. 22 Financial Quick Takes: Genmab-J&J, Adaptimmune, Revolution, PDC*line

Final sales milestone for Darzalex awards Genmab $150M under J&J deal
Genmab A/S (CSE:GMAB; NASDAQ:GMAB) will receive $150 million from the Janssen Biotech Inc. unit of Johnson & Johnson (NYSE:JNJ) after 2019 sales of multiple

Read the full 344 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE